Clinical relevance of intestinal barrier dysfunction in common gastrointestinal diseases.
| Autor: | Muehler A; Immunic, AG, Gräfelfing 82166, Germany. andreas.muehler@imux.com., Slizgi JR; Immunic, AG, Gräfelfing 82166, Germany., Kohlhof H; Immunic, AG, Gräfelfing 82166, Germany., Groeppel M; Immunic, AG, Gräfelfing 82166, Germany., Peelen E; Immunic, AG, Gräfelfing 82166, Germany., Vitt D; Immunic, AG, Gräfelfing 82166, Germany. |
|---|---|
| Jazyk: | angličtina |
| Zdroj: | World journal of gastrointestinal pathophysiology [World J Gastrointest Pathophysiol] 2020 Dec 12; Vol. 11 (6), pp. 114-130. |
| DOI: | 10.4291/wjgp.v11.i6.114 |
| Abstrakt: | The intestinal barrier is a complex and well-controlled physiological construct designed to separate luminal contents from the bowel wall. In this review, we focus on the intestinal barrier's relationship with the host's immune system interaction and the external environment, specifically the microbiome. The bowel allows the host to obtain nutrients vital to survival while protecting itself from harmful pathogens, luminal antigens, or other pro-inflammatory factors. Control over barrier function and the luminal milieu is maintained at the biochemical, cellular, and immunological level. However, disruption to this highly regulated environment can cause disease. Recent advances to the field have progressed the mechanistic understanding of compromised intestinal barrier function in the context of gastrointestinal pathology. There are numerous examples where bowel barrier dysfunction and the resulting interaction between the microbiome and the immune system has disease-triggering consequences. The purpose of this review is to summarize the clinical relevance of intestinal barrier dysfunction in common gastrointestinal and related diseases. This may help highlight the importance of restoring barrier function as a therapeutic mechanism of action in gastrointestinal pathology. Competing Interests: Conflict-of-interest statement: Dr. Muehler and other co-authors report a relationship with Immunic AG (stock, stock options, employment), with drug development projects relevant to this work. In addition, Immunic AG has licensed patent WO 2008/138943 A2 which is part of the development projects in the area of gastrointestinal diseases. Other authors have no conflicts of interest. (©The Author(s) 2020. Published by Baishideng Publishing Group Inc. All rights reserved.) |
| Databáze: | MEDLINE |
| Externí odkaz: |
|